Three FDA- approved oral contraceptives from Afaxys Pharmaceuticals, a division of Afaxys, Inc., are now preferred OCs, as per a recent ruling by Pennsylvania's Medicaid system. The three Afaxys Pharmaceuticals generic contraceptives now available throughout the nation are:. Available only to the public health sector, and authorized, non-retail pre
Upon conclusion of the meeting, the Board of Directors issued the following statement: "We appreciate the support of Teva's shareholders in our efforts to diversify the Board and strengthen our corporate governance, including reducing the size of the Board from 15 members to 13, nominating a director with extensive global pharmaceutical experience,
Hospira is a provider of injectable pharmaceutical drugs and infusion technologies that it develops, manufactures, distributes and markets globally. Through a broad, integrated product portfolio, Hospira is uniquely positioned to Advance Wellness? by improving patient and caregiver safety while reducing healthcare costs. Hospira's portfolio of...
Other new capabilities at the Shanghai site will include a dissolution lab for generic drug stability studies, a mycoplasma lab focused on the biological market, and a highly active compound testing laboratory to meet growing market demand. The investment in the Shanghai facility, and the increased and enhanced service offerings that will result, a
As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada. We are pleased to work with our collaborator, Sandoz Canada, on the launch of this important generic drug. " On July 16, 2014,
Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for desoximetasone topical spray 0.25% and that it has notified Taro Pharmaceuticals U.S.A., Inc., the owner of the Reference Listed Drug of its filing. On July 28, 2014, Taro filed suit against Perrigo in the United States D
Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products.According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in...
Decision Resources Group finds that the majority of surveyed pharmacy and medical directors in the United States believe that the key drivers of biosimilar market penetration will be the level of savings achievable by their managed care organizations and the expected lower cost to patients. Biosimilars first: Interviewed European payers indicate
What is the value of the generic and innovative drugs market in Poland, in Romania, Slovakia, the Czech Republic, Hungary and Bulgaria? Generic and innovative drugs market in Central Europe, comparative analysis, reimbursement policies and development forecasts for 2014-2018 is a comprehensive guide to the market and all its conditions and variable
Medicines360 and Actavis reported that the U.S. Food and Drug Administration has accepted for filing Medicines360's New Drug Application for Levosert, a hormonal intrauterine contraceptive for use by women to prevent pregnancy. According to a media release, in June 2013, Medicines360 and Actavis announced that they had entered into a partnership th
Pfizer Inc. reported financial results for second-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment; the Global Vaccines, Oncology and Consumer Healthcare segment; and.
Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData provides in-depth analysis of the current and future growth drivers of the biosimilars industry. Overview of Key Players in Global Biosimilars Market:? Hospira? Actavis? Pfizer? Sandoz? Stada Arzneimittel? Gedeon Richter? Kyowa
By a News Reporter-Staff News Editor at Pharma Business Week Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded...
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Animal Generic Drug User Fee Cover Sheet" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Col
By a News Reporter-Staff News Editor at Cardiovascular Week Boston, MA- Generic versions of the same prescription drug are clinically interchangeable but often look different depending on the manufacturer. Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women's Hospital have found that var
By a News Reporter-Staff News Editor at Biotech Business Week Coherus BioSciences http://www.coherus.com/>, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept, in chronic plaque psoriasis. "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide supp
By a News Reporter-Staff News Editor at Pharma Business Week Depomed, Inc. announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise prior to the Court's issu
Release date- 25072014- MELBOURNE, Australia- Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd., reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director and for each of the other proposals on the agenda for consideration at the Comp
July 28 Drug developer Mapi Pharma, which was scheduled to complete a $37 million financing round at the end of last week, published a revised prospectus on Friday for raising only $20 million. Mapi Pharma is not bringing a great dream to its offering, while on the other hand, it does not present a well-oiled generic operation with reliable reven
By a News Reporter-Staff News Editor at Managed Care Weekly Digest Fresh data on Medicare and Medicaid are presented in a new report. According to news reporting from Pittsburgh, Pennsylvania, by NewsRx journalists, research stated, "Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs. Generic co
Research and Markets has announced the addition of the "The World Market for Biosimilars, 4th Edition" report to its offerings. In a release, Research and Markets noted that report highlights include:. -Beijing Four Rings Biopharmaceutical Co Ltd.
Mumbai: Wockhardt Ltd, which denied stake-sale rumours on Friday following an unusual spurt in its stock price, is in the final stages of receiving much-awaited regulatory approvals for its Chikalthana unit in Maharashtra. When contacted by dna regarding possible audits, FDA spokesperson Christopher Kelly said, "The Wockhardt facilities that were p
Mumbai: Bangalore- based Biocon on Friday said it has filed its first abbreviated new drug applications targeting the US generics market during the June quarter. The biotechnology company has reported a 9% increase in its net profit at Rs 102.91 crore for the quarter ended June 2014 compared with Rs 93.5 crore posted during the corresponding period